Biotech and Pharmaceuticals Biotechnology

More

  • MediWound makes US market debut Thursday, 20 Mar 2014 | 10:48 AM ET
    MediWound makes US market debut

    MediWound develops treatments for severe burns and hard to heal wounds. Gal Cohen, MediWound CEO, discusses his company's medical solutions and the results of its IPO.

  • Pisani: Momentum names holding up Friday, 14 Mar 2014 | 3:42 PM ET
    Pisani: Momentum names holding up

    CNBC's Bob Pisani discusses the IPO of Castlight Health and how classic momentum stocks are trading, and CNBC's Sheila Dharmajan looks at what biotech stocks are getting hit hard.

  • Biotech bubble formation? Friday, 14 Mar 2014 | 12:46 PM ET
    Biotech bubble formation?

    CNBC's Bertha Coombs discusses potential froth in the biotech sector due to an uptick in biotechnology IPOs.

  • XBI is 'best way to biotech': Trader Wednesday, 12 Mar 2014 | 12:45 PM ET
    XBI is 'best way to biotech': Trader

    FMHR traders Mike Murphy and Pete Najarian debate the play on the S&P biotech ETF.

  • Believe in strong Europe reimbursement: Dendreon CEO Wednesday, 5 Mar 2014 | 5:29 PM ET
    Believe in strong Europe reimbursement: Dendreon CEO

    Biotech firm Dendreon is set to begin selling its prostate cancer vaccine "Provenge" in Europe. John Johnson, Dendreon chairman & CEO, discusses the European launch and addresses investor concerns.

  • Buy Regeneron today: Pro Wednesday, 5 Mar 2014 | 2:40 PM ET
    Buy Regeneron today: Pro

    Sam Isaly of OrbiMed Advisors, explains why he likes the new products of Regeneron, and why he expects Intermune to go higher.

  • Hot health care trades Tuesday, 25 Feb 2014 | 12:15 PM ET
    Hot health care trades

    CNBC's Bertha Coombs reports on which sectors and stocks are impacted by Obamacare, and the FMHR traders share their top health care stock picks.

  • Best biotech stock plays Thursday, 20 Feb 2014 | 2:40 PM ET
    Best biotech stock plays

    Barbara Ryan, FTI Consulting managing director, analyzes the biotech sector and reveals which companies are on the forefront of therapies worth investing in.

  • Pharma for man's best friend Monday, 10 Feb 2014 | 3:17 PM ET
    Pharma for man's best friend

    Steven St. Peter, Aratana Therapeutics president & CEO, discusses the need for pet medical pharmaceuticals and the market for pet insurance.

  • Biotech boom keeps going Wednesday, 29 Jan 2014 | 1:45 PM ET
    Biotech boom keeps going

    CNBC's Sheila Dharmarajan reports on what factors contribute to the biotech sector outperforming this year.

  • Bristol-Myers Squibb performance was staggering: Analyst

    As Bristol-Myers Squibb prepares to report its Q4 earnings on Friday, CNBC's Morgan Brennan and Seamus Fernandez, Leerink Partners managing director & pharma analyst, discuss if now is the time to invest in the biotech.

  • Biotech: 2014's favored child Thursday, 16 Jan 2014 | 12:15 PM ET
    Biotech: 2014's favored child

    Mark Schoenebaum, ISI Group analyst, breaks down the red hot biotech sector and explains why Gilead Sciences is his best play.

  • Twitter almost impossible to value: Analyst Tuesday, 14 Jan 2014 | 10:50 AM ET
    Twitter almost impossible to value: Analyst

    Dan Fitzpatrick, StockmarketMentor.com president & technical analyst, takes a look at the charts to get a technical read on Twitter. Also a look at why Fitzpatrick likes the biotech sector.

  • Alexandria CEO: Real estate a long-term play Monday, 13 Jan 2014 | 2:38 PM ET
    Alexandria CEO: Real estate a long-term play

    Alexandria Real Estate Equities founder, chairman and CEO Joel Marcus discuss its firm's success, and how rising yields impact its dividend.

  • Alexandria CEO: Top tenants looking for more space Monday, 13 Jan 2014 | 2:36 PM ET
    Alexandria CEO: Top tenants looking for more space

    Alexandria Real Estate Equities founder, chairman and CEO Joel Marcus discuss real estate demand in the biotech industry.

  • Perrigo CEO: Got to get our name out Monday, 13 Jan 2014 | 2:24 PM ET
    Perrigo CEO: Got to get our name out

    Perrigo CEO Joseph Papa provides insight on the current flu season, and how it plans on getting its name better known.

  • Perrigo CEO: Elan purchase lowers tax rate Monday, 13 Jan 2014 | 2:24 PM ET
    Perrigo CEO: Elan purchase lowers tax rate

    Perrigo CEO Joseph Papa discusses how its new headquarters in Ireland will impact its tax structure, and whether the company will add a dividend.

  • Biogen CEO: More products, company is focused Monday, 13 Jan 2014 | 2:15 PM ET
    Biogen CEO: More products, company is focused

    Biogen Idec CEO George Scangos discusses the busy year ahead for the company, including the EU launch of Tecfidera and when a dividend will be offered.

  • Monsanto wins high court challenge on seed patents Monday, 13 Jan 2014 | 2:06 PM ET
    A protester against Monsanto genetically modified food in New York's Bryant Park.

    The Supreme Court upheld Monsanto's biotech seed patents on Monday, dealing a blow to organic farmers and critics of the company.

  • Roche now world leader in cancer treatment: Pro Friday, 10 Jan 2014 | 2:45 PM ET
    Roche now world leader in cancer treatment: Pro

    The outlook for biotech is "wonderful," explains Sam Isaly, Orbimed Advisors managing partner.